Pooled analysis of the ENHANCE and RESPONSE phase 3 trials shows seladelpar 10 mg reduces pruritus and sleep disturbance in patients with primary biliary cholangitis (PBC) and moderate-to-severe baseline itch versus placebo over 6 months, with an acceptable safety profile.